pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
22d
STAT+: Federal judge rejects new Medicaid ‘frailty’ definition for work requirements
stat
22d
STAT+: Federal judge rejects new Medicaid ‘frailty’ definition for work requirements
stat
22d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
22d
STAT+: New federal rule will require prescription drug middlemen to share secret payments data
stat
22d
Genmab soars to record highs after cancer drug succeeds in key trial
biopharma dive
22d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
22d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
22d
STAT+: Kennedy’s closing arguments for the 2026 midterms: Fraud, vaccines, and MAHA
stat
22d
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
biospace
22d
Martin Kulldorff critiques scientific gatekeepers at NIH lecture
stat
22d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
22d
STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
stat
23d
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
biospace
23d
The cost of waiting: What reaching clinical proof-of-concept sooner means for biotech cash burn
fiercebiotech
23d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
23d
BioMarin inks up to $475M deal to challenge Fabry ERT incumbents
fiercebiotech
23d
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
stat
23d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
23d
Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes
raps
23d
Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid
fiercebiotech
23d
FDA charts path for approval of individualized gene editing therapies
endpoints
23d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
23d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
23d
FDA unveils guidance for ‘plug and play’ gene therapies
biopharma dive
23d
New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
biospace
23d
GSK vaccine sales miss expectations amid falling demand from adults
biospace
23d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
23d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
← prev
page 8 of 52
next →